 |
|
|
|
|
Table of Contents
- CHAPTER 1 EXECUTIVE SUMMARY
- Key findings
- Historical and forecast ethical sales performance
- Therapeutic strategy
- Launch and expiry outlook
- Externalization, geographic and molecule type strategies
- Externalization strategy
- Geographic strategy
- Molecule type strategy
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
- CHAPTER 2 CORPORATE HISTORY
- Key findings
- Background
- Key corporate developments
- M&A history
- M&A strategy
- Abgenix acquisition
- Alantos & Ilypsa
- Current corporate structure
- CHAPTER 3 HISTORICAL PERFORMANCE
- Key findings
- Introduction
- Revenue and growth rate analysis, 2001-06
- Revenue and growth rate vs. peer set
- Product analysis, 2001-06
- Growth drivers
- Growth resistors
- Operating revenue and cost analysis, 2001-06
- Operating revenue/cost analysis
- CHAPTER 4 FORECAST PERFORMANCE
- Key findings
- Introduction
- Revenue and growth rate, 2006-12
- Product analysis, 2006-12
- Growth drivers
- denosumab (musculoskeletal & oncology)
- Vectibix
- Neulasta
- Enbrel
- Growth resistors
- Epogen (cardiovascular & hematology and oncology)
- Aranesp (cardiovascular & hematology and oncology)
- Neupogen
- Therapy area analysis, 2006-12
- Therapy area growth drivers
- Musculoskeletal
- Oncology
- Other therapy areas
- Therapy area growth resistors
- Cardiovascular & hematology
- Therapy area focus
- Launches and expiries analysis, 2006-12
- Launch portfolio
- Core portfolio
- Expiry portfolio
- Launch/core/expiry configuration
- Externalization analysis, 2006-12
- Geographic analysis, 2006-12
- Molecule type analysis, 2006-12
- CHAPTER 5 KEY PRODUCTS AND COMPETITORS
- Key findings
- Overview
- Amgen' s EPO franchise
- Aranesp
- Overview
- Sales forecast
- Newsflow
- EPO controversy : clinical trial proof
- The fall-out from the clinical trials; new warnings, restrictions
and bad publicity
- Greater restriction of use expected in the US
- Implication' s for Aranesp: Future market assessment
- Epogen
- Overview
- Sales forecast
- Future market assessment
- Oncology
- Neulasta
- Overview
- Sales forecast
- Newsflow
- Current market position - marketing, reimbursement and lifecycle
management
- Future growth
- Vectibix
- Overview
- Sales forecast
- Newsflow
- Future market assessment
- Immunology & inflammation
- Enbrel
- Overview
- Sales forecast
- Newsflow
- Musculoskeletal
- denosumab
- Overview
- Sales forecast
- Newsflow
- Future market potential
- R&D pipeline
- CHAPTER 6 APPENDIX
- IMS vs. company-reported data reconciliation
- References
- Abbreviations
- List of Tables
- Table 1: Peer set overview
- Table 2: Operating revenue/cost analysis ($m), 2001-06
- Table 3: Operating cost ratio analysis (% of total revenues), 2001-06
- Table 4: Product portfolio overview, sales ($m), 2006-12
- Table 5: Therapy area overview, sales ($m), 2006-12
- Table 6: Launch portfolio overview, sales ($m), 2006-12
- Table 7: Core portfolio overview, sales ($m), 2006-12
- Table 8: Expiry portfolio overview, sales ($m), 2006-12
- Table 9: Externally developed portfolio ($m), 2006-12
- Table 10: Molecule type overview, sales ($m), 2006-12
- Table 11: Key products overview
- Table 12: Aranesp: overview
- Table 13: Aranesp (total brand): sales forecast ($m), 2006-12
- Table 14: Aranesp: newsflow
- Table 15: Aranesp (oncology): sales forecast ($m), 2006-12
- Table 16: Aranesp (CV): sales forecast ($m), 2006-12
- Table 17: Epogen: overview
- Table 18: Epogen (total brand): sales forecast ($m), 2006-12
- Table 19: Epogen (oncology): sales forecast ($m), 2006-12
- Table 20: Epogen (oncology): sales forecast ($m), 2006-12
- Table 21: Neulasta: overview
- Table 22: Neulasta: sales forecast ($m), 2006-12
- Table 23: Neulasta: newsflow
- Table 24: Vectibix: overview
- Table 25: Vectibix: sales forecast ($m), 2006-12
- Table 26: Vectibix: newsflow
- Table 27: Enbrel: overview
- Table 28: Enbrel: sales forecast ($m), 2006-12
- Table 29: Enbrel: newsflow
- Table 30: Denosumab: overview
- Table 31: denosumab: sales forecast ($m), 2006-12
- Table 32: denosumab: newsflow
- Table 33: Amgen R&D pipeline (Phase I-registration)
- List of Figures
- Figure 1: Historical and forecast ethical sales performance (% CAGR),
Amgen and Big Pharma peer set
- Figure 2: Therapeutic focus vs. biotech peer set (%), 2006
- Figure 3: Launch, core and expiry, absolute sales growth, 2006-12
(sales as % of 2006 sales), Amgen
- Figure 4: Launch, core and expiry, absolute sales growth, 2006-12
(sales as % of 2006 sales), peer set
- Figure 5: Molecule type, externalization and geographic market
dependency (%) vs. peer set, 2006
- Figure 6: Molecule type, externalization and geographic market
dependency (%) vs. peer set, 2012
- Figure 7: SWOT analysis of Amgen
- Figure 8: Amgen timeline
- Figure 9: M&A/divestment history
- Figure 10: Current corporate structure
- Figure 11: Revenue & growth rate (ethical sales) ($m), 2001-06
- Figure 12: Ethical revenue ($m) and growth rate (%) vs. peer set,
2001-06
- Figure 13: Growth drivers/resistor products of historical revenue
performance ($m), 2001-06
- Figure 14: Operating revenue/cost analysis ($m), 2001-06
- Figure 15: Operating cost ratio analysis (% of total revenues), 2001-06
- Figure 16: Ethical revenue ($m) and growth rate (%), 2006-12
- Figure 17: Top five products by sales ($m), 2006
- Figure 18: Top five products by sales ($m), 2012
- Figure 19: Growth drivers and resistors by product, 2006-12
- Figure 20: Key strategic products, sales ($m), 2006-12
- Figure 21: Ethical sales by therapy area ($m), 2006-12
- Figure 22: Growth drivers and resistors by therapy area ($m), 2006-12
- Figure 23: Ethical sales by therapy area (%), 2006-12
- Figure 24: Therapy area focus compared with peer set (% total ethical
sales), 2006
- Figure 25: Therapy area focus compared with peer set (% total ethical
sales), 2012
- Figure 26: Launch schedule, sales ($m), 2006-12
- Figure 27: Core products sales growth ($m), 2006-12
- Figure 28: Expiry schedule, sales ($m), 2006-12
- Figure 29: Launch, core and expiry, sales ($m), 2006-12
- Figure 30: Launch, core and expiry, absolute sales growth, 2006-12
(sales as % of 2006 sales), Amgen
- Figure 31: Launch, core and expiry, absolute sales growth, 2006-12
(sales as % of 2006 sales), peer set
- Figure 32: Externalization dependency, sales ($m), 2006-12
- Figure 33: Growth drivers and resistors, externally vs. internally
discovered products, sales ($m), 2006-12
- Figure 34: Externalization dependency vs. peer set, % total sales, 2006
- Figure 35: Externalization dependency vs. peer set, % total sales, 2012
- Figure 36: Geographical sales breakdown ($m), 2006-12
- Figure 37: Growth drivers and resistors by geography, sales ($m),
2006-12
- Figure 38: US dependency vs. peer set, % total sales, 2006
- Figure 39: US dependency vs. peer set, % total sales, 2012
- Figure 40: Molecule type sales breakdown ($m), 2006-12
- Figure 41: Growth drivers and resistors by molecule type, sales ($m),
2006-12
- Figure 42: Biologics dependency vs. peer set, % total sales, 2006
- Figure 43: Biologics dependency vs. peer set, % total sales, 2012
- Figure 44: Aranesp provides Amgen access to the US chemotherapy, EU
dialysis and EU chemotherapy market segments
- Figure 45: IMS vs. company-reported ethical sales discrepancy ($m),
2006
- Figure 46: IMS vs. company-reported ethical sales forecast growth
rates (%), 2006-12
|
|
|
|
|
|
View Cart
